SRDX News and Press, Surmodics Inc. From 02/13/23

Surmodics, Inc. ( NASDAQ: SRDX ) lost sharply on Monday after Needham downgraded the medical device maker to Hold from Buy, citing uncertain prospects for the company’s investigational drug-coated balloon SurVeil. In January, Surmodics ( SRDX ) announced a reduction of 13% ...

Surmodics, Inc. (SRDX) Q1 2023 Earnings Conference Call February 6, 2023 05:00 p.m. ET Company Representatives Gary Maharaj - President, Chief Executive Officer Tim Arens - Chief Financial Officer Conference Call Participants Brooks O'Neil - Lake Street Capital...

Surmodics press release ( NASDAQ: SRDX ): Q1 Non-GAAP EPS of -$0.50 beats by $0.16 . Revenue of $24.9M (+8.3% Y/Y) beats by $0.93M . Fiscal Year 2023 Financial Guidance Surmodics now expects fiscal year 2023 total revenue to range from $102 million to $106 mill...

Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today reported financial results for its first quarter ended December 31, 2022, and updated its financial outlook for its fiscal year ending September 30, 2023. ...

Surmodics ( NASDAQ: SRDX ) is cutting 13% of its workforce in the aftermath of the US FDA's decision in January not to approve its SurVeil drug-coated balloon . The company expects restructuring charges of $1M-$1.2M in fiscal 2023 Q2, the same quarter the layoffs will take place...

Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This report optimizes trading in ...

Earnings Conference Call and Webcast Will Begin at 4:00 p.m. (CT) Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced that first quarter of fiscal year 2023 financial results will be releas...

Boston, Massachusetts--(Newsfile Corp. - January 25, 2023) - Block & Leviton is investigating Surmodics, Inc. (NASDAQ: SRDX) for potential securities law violations. Investors who have lost money in their Surmodics investment should contact the firm to learn more about how they might recove...

Surmodics, Inc. ( NASDAQ: SRDX ) shares approached a three-year low on Thursday after the MedTech company announced that the FDA said its premarket approval application for the SurVeil drug-coated balloon was not approvable in the current form. In a letter to the company, the agency r...

Surmodics’ proprietary Crystalline Drug Release (CDR) platform enhances sirolimus stability, transfer, and retention in tissue CDR discussed in connection with 12-month data from Surmodics’ SWING trial of the Sundance™ Sirolimus-Coated Balloon Surmodics, Inc. (N...